Angiogenesis Receptor Tyrosine Kinase Antibody Sampler Kit #78451
Product Information
Kit Usage Information
Protocols
- 2478: Western Blotting
- 3166: Western Blotting, Immunoprecipitation (Magnetic)
- 3169: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), IF-F Citrate Retrieval (Rabbit), Immunofluorescence
- 4221: Western Blotting
- 7074: Western Blotting
- 7403: Western Blotting
- 9698: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 9740: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 50661: Western Blotting, Immunoprecipitation (Magnetic)
- 52928: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence
Product Description
Background
Angiogenesis is defined as the physiological process by which new blood vessels are formed from pre-existing blood vessels. It is a critical process that enables specific physiological conditions in healthy adults, including development, skeletal muscle hypertrophy, and wound healing (1,2). Angiogenesis can be aberrantly activated to generate new blood vessels during pathological conditions such as cancer, neovascular disorders, and chronic inflammation. Angiogenesis is a complicated process regulated by multiple mechanisms and pathways (3). VEGFR2 is a member of the family of receptor tyrosine kinases (RTKs) mainly located in endothelial cells and is a major player in angiogenesis. VEGF-VEGFR2 ligand-receptor activation is the key signaling pathway for angiogenesis activation (4,5). Multiple non-VEGF RTK activations can replace VEGFR to promote angiogenesis (6,7), including PDGFR (9), FGFR (8), and Tie2 (10). These RTKs are targets for an antiangiogenic based disease treatment (11,12).
- Malapelle, U. and Rossi, A. (2019) Expert Opin Emerg Drugs 24, 71-81.
- Chung, A.S. et al. (2010) Nat Rev Cancer 10, 505-14.
- Jain, R.K. (2003) Nat Med 9, 685-93.
- Leung, D.W. et al. (1989) Science 246, 1306-9.
- Jeltsch, M. et al. (2013) Cold Spring Harb Perspect Biol 5, a009183. doi: 10.1101/cshperspect.a009183.
- Zhao, Y. and Adjei, A.A. (2015) Oncologist 20, 660-73.
- Vimalraj, S. (2022) Int J Biol Macromol 221, 1428-1438.
- Lieu, C. et al. (2011) Clin Cancer Res 17, 6130-9.
- Hellberg, C. et al. (2010) Recent Results Cancer Res 180, 103-14.
- Duran, C.L. et al. (2021) Cancers (Basel) 13, 5730. doi: 10.3390/cancers13225730.
- Ramjiawan, R.R. et al. (2017) Angiogenesis 20, 185-204.
- Socinski, M.A. (2011) Cancer Treat Rev 37, 611-7.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.